`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`ARGENTUM PHARMACEUTICALS LLC
`
`Petitioner
`
`v.
`
`CIPLA LIMITED
`
`Patent Owner
`
`_____________________
`
`Case No. IPR2017-00807
`
`U.S. Patent No. 8,168,620
`_____________________
`
`JOINT MOTION TO TERMINATE PROCEEDINGS
`PURSUANT TO 35 U.S.C. § 317
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-00807
`Joint Motion to Terminate
`
`As authorized in the Patent Trial and Appeal Board’s e-mail dated May 16,
`
`2018, and pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. §§ 42.72 and 42.74, Patent
`
`Owner and Petitioner jointly and respectfully request that the inter partes review
`
`(“IPR”) of U.S. Patent No. 8,168,620 be terminated.
`
`I.
`
`Statement of Relief Requested
`
`Pursuant to 35 U.S.C. § 317, 37 C.F.R. § 42.72, and 37 C.F.R. § 42.74, and
`
`pursuant to the authorization to file this motion provided by the Board with the
`
`parties on May 16, 2018, Petitioner Argentum Pharmaceuticals LLC (“Argentum”)
`
`and Patent Owner Cipla Limited (“Cipla”) jointly request the termination of this
`
`inter partes review of U.S. Patent No. 8,168,620 in its entirety as a result of
`
`settlement between Petitioner and Patent Owner.
`
`The parties have settled their dispute and executed a settlement agreement to
`
`terminate this inter partes review.
`
`The parties’ settlement agreement has been made in writing, and a true and
`
`correct copy is being filed concurrently herewith as Exhibit 2183. The parties are
`
`also filing concurrently herewith a joint request to treat the settlement agreement as
`
`business confidential information and keep it separate from the files of the IPR and
`
`the involved patent pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b) and
`
`(c).
`
`
`
`- 1 -
`
`
`
`
`
`
`II.
`
`Statement of Facts
`
`
`
`
`IPR2017-00807
`Joint Motion to Terminate
`
`Petitioner filed this IPR petition on February 2, 2017. On August 21, 2017,
`
`the Board instituted inter partes review of claims 1, 4-6, 24-26, 29, and 42-44 of
`
`the ’620 patent. On May 15, 2018, Petitioner and Patent Owner entered into a
`
`settlement agreement. See CIP2183 (Confidential). Argentum agrees to terminate
`
`this IPR proceeding.
`
`The Board has not yet decided the merits of the pending IPR proceeding.
`
`III. Argument
`35 U.S.C. § 317(a) provides: “An inter partes review instituted under this
`
`chapter shall be terminated with respect to any petitioner upon the joint request of
`
`the petitioner and the patent owner, unless the Office has decided the merits of the
`
`proceeding before the request for termination is filed.” 35 U.S.C. § 317(a).
`
`Similarly, 37 C.F.R. § 42.72 provides that “[t]he Board may terminate a trial
`
`without rendering a final written decision, where appropriate, including where the
`
`trial is consolidated with another proceeding or pursuant to a joint request under 35
`
`U.S.C. 317(a).”
`
`The Trial Practice Guide additionally counsels that “[t]here are strong public
`
`policy reasons to favor settlement between the parties to proceeding” and that the
`
`Board “expects that a proceeding will terminate after the filing of a settlement
`
`agreement, unless the Board has already decided the merits of the proceeding. 35
`
`
`
`- 2 -
`
`
`
`
`
`
`U.S.C. 317(a), as amended, and 35 U.S.C. 327.” Office Patent Trial Practice
`
`IPR2017-00807
`Joint Motion to Terminate
`
`
`
`
`Guide, 77 Fed. Reg. 48,756, 48,768 (Aug. 14, 2012).
`
`A.
`
` Termination of this proceeding is proper.
`
`As noted in the Statement of Facts, oral argument has not yet occurred.
`
`Thus, the Board has not yet “decided the merits of the proceeding before the
`
`request for termination is filed.” 35 U.S.C. § 317(a); 77 Fed. Reg. 48768 (“The
`
`Board expects that a proceeding will terminate after the filing of a settlement
`
`agreement, unless the Board has already decided the merits of the proceeding.”).
`
`The Board has already cancelled the oral hearing that was scheduled to take place
`
`in this proceeding. Further, the parties are unaware of any other matter before the
`
`Board that would be affected by the outcome of this proceeding. Accordingly, the
`
`parties respectfully request that the Board terminate the inter partes review of U.S.
`
`Patent No. 8,168,620.
`
`In the past, the Board has terminated the entire proceedings based on joint
`
`motions to terminate even after the merits had been fully briefed and the matter
`
`was ready for oral argument, or even after oral argument. See Toyota Motor Corp.
`
`v. Blitzsafe Tex. LLC, IPR2016-00421, Paper 28 (Feb. 21, 2017) (granting motion
`
`to terminate even after all substantive papers were filed, “particularly in light of the
`
`fact that a final written decision is not due until more than four months from
`
`now”); Plaid Techs., Inc. v. Yodlee, Inc., IPR2016-00273, Paper 29 (Feb. 8, 2017)
`
`
`
`- 3 -
`
`
`
`
`
`
`(granting motion to terminate because “the parties’ joint motions to terminate were
`
`IPR2017-00807
`Joint Motion to Terminate
`
`
`
`
`filed prior to the oral hearings in these cases”); Apex v. Resmed, IPR2013-00512,
`
`Paper 39 (Sept. 12, 2014) (granting joint motion to terminate after the parties had
`
`fully briefed the matter); Rackspace Hosting, Inc. v. Clouding IP, LLC, CBM2014-
`
`00034, Paper 28 (Dec. 9, 2014) (granting motion to terminate after close of
`
`evidentiary record and less than ten days before trial); Volution v. Versata
`
`Software, CBM2013-00018, Paper 52 (June 17, 2014) (granting motion to
`
`terminate after oral argument).
`
`Further, because the Board has yet to conduct an oral hearing and issue a
`
`decision on the merits, termination of the entire proceeding would save the Board
`
`significant administrative resources. Termination would also further AIA’s purpose
`
`of providing an efficient and less costly alternative forum for patent disputes and
`
`its encouragement for settlement.
`
`IV. Related Litigations Involving The Patent At Issue
`Litigations involving the patent at issue in this proceeding are set forth
`
`below. As shown below, none of these litigations is currently pending as each has
`
`been resolved.
`
`Case
`Meda Pharmaceuticals Inc. et al v. Apotex
`Inc. et al., 14-1453-LPS (D. Del.) (filed Dec.
`2, 2014; settled May 17, 2017)
`
`Defendant(s)
`Apotex Inc.
`Apotex Corp.
`
`
`
`- 4 -
`
`
`
`
`
`
`IPR2017-00807
`Joint Motion to Terminate
`
`
`
`
`Meda Pharmaceuticals Inc. et al v. Teva
`Pharmaceuticals USA, Inc., 15-785-LPS (D.
`Del.) (filed Sept. 8, 2015; settled July 28,
`2017)
`Meda Pharmaceuticals Inc. et al v. Perrigo
`UK FINCO Limited Partnership et al., 16-
`794 (D. Del.) (filed Sept. 9, 2016; settled July
`7, 2017)
`
`V. Related Inter Partes Review Proceedings Currently Before The Office
`There are no other inter partes review proceedings currently before the
`
`Teva Pharmaceuticals USA,
`Inc.
`
`
`Perrigo UK FINCO Limited
`Partnership; Perrigo Company;
`Perrigo Pharmaceuticals Co.
`
`Office involving the patent at issue.
`
`VI. Written Settlement Statement
`Pursuant to 37 C.F.R. § 42.74(c), the parties are filing herewith as CIP2183
`
`a true copy of the settlement agreement entered between the parties on May 16,
`
`2018. The settlement agreement was entered into in contemplation of termination
`
`of this proceeding.
`
`Petitioner and Patent Owner respectfully request that the Board grant the
`
`parties’ Joint Motion to Terminate this proceeding in its entirety and grant the
`
`request to treat the settlement agreement between the parties as business
`
`confidential information.
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`/Michael Houston/
`
`- 5 -
`
`
`
`
`
`
`Date: May 17, 2018
`
`
`
`
`Date: May 17, 2018
`
`
`
`
`
`
`
`
`
`IPR2017-00807
`Joint Motion to Terminate
`
`Michael R. Houston
`Reg. No. 58,486
`Lead Attorney for Petitioner
`
`
`Respectfully submitted,
`
`
`/Dennies Varughese/
`Dennies Varughese
`Registration No. 61,868
`Lead Attorney for Patent Owner
`
`
`
`
`
`- 6 -
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies
`
`that
`
`the above-captioned “JOINT
`
`MOTION TO TERMINATE PROCEEDINGS PURSUANT TO 35 U.S.C. § 317”
`
`was served in its entirety on May 17, 2018, upon the following parties via
`
`electronic mail upon the following counsel of record for the Petitioner:
`
`Michael R. Houston: mhouston@foley.com
`Joseph P. Meara: jmeara@foley.com
`James P. McParland: jmcparland@foley.com
`Tyler C. Liu: TLiu@agpharm@foley.com
`ARG-dymista@foley.com
`
`FOLEY & LARDNER LLP
`321 North Clark Street
`Suite 2800
`Chicago, IL 60654
`
`
`
`
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`Dennies Varughese
`Registration No. 61,868
`Lead Attorney for Patent Owner
`
`
`
`
`Date: May 17, 2018
`1100 New York Avenue, N.W.
`Washington, D.C. 20005
`(202) 371-2600
`
`9355960.1
`
`
`